MX390417B - Tratamiento de enfermedades colestasicas intrahepaticas. - Google Patents

Tratamiento de enfermedades colestasicas intrahepaticas.

Info

Publication number
MX390417B
MX390417B MX2018014915A MX2018014915A MX390417B MX 390417 B MX390417 B MX 390417B MX 2018014915 A MX2018014915 A MX 2018014915A MX 2018014915 A MX2018014915 A MX 2018014915A MX 390417 B MX390417 B MX 390417B
Authority
MX
Mexico
Prior art keywords
treatment
intrahepatic cholestatic
cholestatic diseases
diseases
intrahepatic
Prior art date
Application number
MX2018014915A
Other languages
English (en)
Spanish (es)
Other versions
MX2018014915A (es
Inventor
Charles A Mcwherter
Pol Boudes
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2018014915A publication Critical patent/MX2018014915A/es
Publication of MX390417B publication Critical patent/MX390417B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2018014915A 2016-05-31 2017-04-26 Tratamiento de enfermedades colestasicas intrahepaticas. MX390417B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (2)

Publication Number Publication Date
MX2018014915A MX2018014915A (es) 2019-04-24
MX390417B true MX390417B (es) 2025-03-20

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018014915A MX390417B (es) 2016-05-31 2017-04-26 Tratamiento de enfermedades colestasicas intrahepaticas.

Country Status (27)

Country Link
US (5) US10272058B2 (OSRAM)
EP (1) EP3463328B1 (OSRAM)
JP (1) JP7079735B2 (OSRAM)
KR (1) KR102408288B1 (OSRAM)
CN (1) CN109195594A (OSRAM)
AU (1) AU2017274293B2 (OSRAM)
BR (1) BR112018074147A2 (OSRAM)
CA (1) CA3024155C (OSRAM)
CY (1) CY1125465T1 (OSRAM)
DK (1) DK3463328T3 (OSRAM)
ES (1) ES2921230T3 (OSRAM)
HR (1) HRP20220903T1 (OSRAM)
HU (1) HUE059838T2 (OSRAM)
IL (1) IL263372B2 (OSRAM)
LT (1) LT3463328T (OSRAM)
MX (1) MX390417B (OSRAM)
NZ (1) NZ748721A (OSRAM)
PL (1) PL3463328T3 (OSRAM)
PT (1) PT3463328T (OSRAM)
RS (1) RS63345B1 (OSRAM)
RU (1) RU2765460C2 (OSRAM)
SG (1) SG11201810123SA (OSRAM)
SI (1) SI3463328T1 (OSRAM)
SM (1) SMT202200471T1 (OSRAM)
UA (1) UA122719C2 (OSRAM)
WO (1) WO2017209865A1 (OSRAM)
ZA (1) ZA201808360B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
AU2019378845A1 (en) * 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
DK4225291T3 (da) * 2021-02-01 2024-05-27 Cymabay Therapeutics Inc Behandling af cholangiopati med seladelpar

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6222025B1 (en) 1995-03-06 2001-04-24 Isis Pharmaceuticals, Inc. Process for the synthesis of 2′-O-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
JP4293636B2 (ja) 1996-02-14 2009-07-08 アイシス・ファーマシューティカルス・インコーポレーテッド 糖修飾ギャップ付オリゴヌクレオチド
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
PL1667964T3 (pl) 2003-09-19 2010-01-29 Janssen Pharmaceutica Nv Kwasy 4-((fenoksyalkilo)tio)-fenoksyoctowe i analogi
ES2399721T5 (es) 2004-03-05 2016-05-25 Univ Pennsylvania Métodos para tratar trastornos o enfermedades asociados a la hiperlipidemia e hipercolesterolemia minimizando los efectos adversos
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2010045361A1 (en) 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR20130073884A (ko) 2010-03-30 2013-07-03 노파르티스 아게 Dgat1 억제제의 용도
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
EP3071198A1 (en) 2013-11-20 2016-09-28 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
PL3119384T3 (pl) 2014-03-20 2019-03-29 Cymabay Therapeutics, Inc. Leczenie wewnątrzwątrobowych chorób cholestatycznych
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CN106163508A (zh) 2014-04-11 2016-11-23 西玛贝医药公司 Nafld和nash的治疗
WO2015200580A1 (en) 2014-06-26 2015-12-30 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3973959B8 (en) 2017-09-26 2025-01-15 CymaBay Therapeutics, Inc. Treatment of cholestatic pruritus with seladelpar
AU2019378845A1 (en) 2018-11-16 2021-06-03 Cymabay Therapeutics, Inc. Combination treatment of NAFLD and NASH
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications

Also Published As

Publication number Publication date
JP7079735B2 (ja) 2022-06-02
US10272058B2 (en) 2019-04-30
AU2017274293A1 (en) 2018-12-13
CY1125465T1 (el) 2025-05-09
HRP20220903T1 (hr) 2022-10-14
MX2018014915A (es) 2019-04-24
CA3024155A1 (en) 2017-12-07
RU2018146504A (ru) 2020-07-09
IL263372A (en) 2018-12-31
EP3463328A1 (en) 2019-04-10
HUE059838T2 (hu) 2023-01-28
NZ748721A (en) 2022-04-29
PT3463328T (pt) 2022-07-07
AU2017274293B2 (en) 2022-03-31
US20170340589A1 (en) 2017-11-30
BR112018074147A2 (pt) 2019-03-06
EP3463328B1 (en) 2022-06-15
US20210220305A1 (en) 2021-07-22
RS63345B1 (sr) 2022-07-29
KR102408288B1 (ko) 2022-06-10
ES2921230T3 (es) 2022-08-22
SI3463328T1 (sl) 2022-08-31
US20200061006A1 (en) 2020-02-27
RU2765460C2 (ru) 2022-01-31
UA122719C2 (uk) 2020-12-28
JP2019518022A (ja) 2019-06-27
US10813895B2 (en) 2020-10-27
PL3463328T3 (pl) 2022-10-03
SG11201810123SA (en) 2018-12-28
US20190255004A1 (en) 2019-08-22
KR20190015363A (ko) 2019-02-13
US10478411B2 (en) 2019-11-19
ZA201808360B (en) 2020-02-26
US20210000774A1 (en) 2021-01-07
US11596614B2 (en) 2023-03-07
DK3463328T3 (da) 2022-07-04
CA3024155C (en) 2023-10-10
IL263372B2 (en) 2023-06-01
US11000494B2 (en) 2021-05-11
CN109195594A (zh) 2019-01-11
WO2017209865A1 (en) 2017-12-07
SMT202200471T1 (it) 2023-01-13
RU2018146504A3 (OSRAM) 2020-07-27
LT3463328T (lt) 2022-08-10

Similar Documents

Publication Publication Date Title
MX369921B (es) Tratamiento de la hgna y ehna.
EP3813808A4 (en) Methods of treating substance abuse
KR102199943B9 (ko) 의료용 자극 장치
MX367478B (es) Tratamiento de enfermedades colestasicas intrahepaticas.
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
DK3360508T3 (da) Hjælpeanordning til dental behandling
EP3448263A4 (en) Electrotherapeutic treatment
MX392537B (es) Tratamiento del prurito colestasico.
PT3458052T (pt) Tratamento combinado do cancro
LT3458610T (lt) Krūties vėžio terapinis gydymas, remiantis c-maf būkle
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
MX390417B (es) Tratamiento de enfermedades colestasicas intrahepaticas.
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
HUE053648T2 (hu) Gyógyászati kombinációk rák kezelésére
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EP3383449A4 (en) IMPLANTABLE KIDNEY THERAPY THERAPY
EP3852816A4 (en) METHODS OF TREATMENT OF CANCER
LT3352857T (lt) T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985
IL259381B (en) Mirabegron for the treatment of retinal diseases
ITUA20162868A1 (it) Apparato di trattamento di una scocca
PL3302499T3 (pl) Leczenie chorób mitochondrialnych
LT3322438T (lt) Il-8 inhibitoriai, skirti naudoti tam tikrų urologinių susirgimų gydymui
PL3903774T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych